These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27102443)

  • 1. Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy.
    Kim DG; Kim KH; Seo YJ; Yang H; Marcusson EG; Son E; Lee K; Sa JK; Lee HW; Nam DH
    Oncotarget; 2016 May; 7(20):29400-11. PubMed ID: 27102443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept.
    Halle B; Marcusson EG; Aaberg-Jessen C; Jensen SS; Meyer M; Schulz MK; Andersen C; Kristensen BW
    J Neurooncol; 2016 Jan; 126(1):47-55. PubMed ID: 26428358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
    Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
    J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
    Chen PY; Ozawa T; Drummond DC; Kalra A; Fitzgerald JB; Kirpotin DB; Wei KC; Butowski N; Prados MD; Berger MS; Forsayeth JR; Bankiewicz K; James CD
    Neuro Oncol; 2013 Feb; 15(2):189-97. PubMed ID: 23262509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic.
    Teplyuk NM; Uhlmann EJ; Gabriely G; Volfovsky N; Wang Y; Teng J; Karmali P; Marcusson E; Peter M; Mohan A; Kraytsberg Y; Cialic R; Chiocca EA; Godlewski J; Tannous B; Krichevsky AM
    EMBO Mol Med; 2016 Mar; 8(3):268-87. PubMed ID: 26881967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
    Wang D; Wang C; Wang L; Chen Y
    Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme.
    Lin YL; Chang KF; Huang XF; Hung CL; Chen SC; Chao WR; Liao KW; Tsai NM
    Int J Nanomedicine; 2015; 10():6009-20. PubMed ID: 26451107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench.
    Burkhardt JK; Hofstetter CP; Santillan A; Shin BJ; Foley CP; Ballon DJ; Pierre Gobin Y; Boockvar JA
    J Clin Neurosci; 2012 Nov; 19(11):1568-72. PubMed ID: 22985932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21.
    Lee TJ; Yoo JY; Shu D; Li H; Zhang J; Yu JG; Jaime-Ramirez AC; Acunzo M; Romano G; Cui R; Sun HL; Luo Z; Old M; Kaur B; Guo P; Croce CM
    Mol Ther; 2017 Jul; 25(7):1544-1555. PubMed ID: 28109960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts.
    Shen Y; Pi Z; Yan F; Yeh CK; Zeng X; Diao X; Hu Y; Chen S; Chen X; Zheng H
    Int J Nanomedicine; 2017; 12():5613-5629. PubMed ID: 28848341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient delivery of anti-miR-210 using Tachyplesin, a cell penetrating peptide, for glioblastoma treatment.
    Jana A; Narula P; Chugh A; Kulshreshtha R
    Int J Pharm; 2019 Dec; 572():118789. PubMed ID: 31726199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
    Dréan A; Goldwirt L; Verreault M; Canney M; Schmitt C; Guehennec J; Delattre JY; Carpentier A; Idbaih A
    Expert Rev Neurother; 2016 Nov; 16(11):1285-1300. PubMed ID: 27310463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma.
    Lakkadwala S; Dos Santos Rodrigues B; Sun C; Singh J
    J Control Release; 2019 Aug; 307():247-260. PubMed ID: 31252036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propolis Extract Regulates microRNA Expression in Glioblastoma and Brain Cancer Stem Cells.
    C Yilmaz U; Bagca BG; Karaca E; Durmaz A; Durmaz B; Aykut A; Kayalar H; Avci CB; Susluer SY; Pariltay E; Gunduz C; Cogulu O
    Anticancer Agents Med Chem; 2022; 22(2):378-389. PubMed ID: 33949939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.
    Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
    Chakrabarti M; Ray SK
    Apoptosis; 2016 Mar; 21(3):312-28. PubMed ID: 26573275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.